Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists uncover hormone clues in obesity and diabetes

NCT ID NCT01982019

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at a recently discovered hormone called 26RFa in 62 women who were obese, some with type 2 diabetes and some without. Researchers measured the hormone levels before and after weight-loss surgery (sleeve gastrectomy) and compared them to healthy-weight volunteers. The goal was to better understand how 26RFa relates to body weight and blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Feb 2014

Finished

Jun 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Patients : 1. Inclusion Criteria: * Obese patients (with or without type 2 diabetes) with a planned sleeve gastrectomy 2. Exclusion Criteria: * HbA1c \>11 %. 2. Healthy volunteers : 1. Inclusion Criteria: * 20 ≤ BMI ≤ 25 kg/m², * with no treatment that may influence the glycemic control, * normal electrocardiogram, * no disturbance of the following blood tests: CBC, serum electrolytes, glucose, * negative serology of HIV, hepatitis B and C, * does not participate at another clinical trial in the last 3 months 2. Exclusion Criteria: * severe medical or surgical history, particularly endocrine or cardiac, * oedema syndrome, * hypertension.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Rouen

    Rouen, Haute Normandie, 76000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.